References
1. ESC Scientific Document Group. 2016 ESC Guidelines for the management
of atrial fibrillation developed in collaboration with EACTS. Eur Heart
J. 2016;37: 2893-2962.
2. Cappato R, Calkins H, Chen SA, Davies W, Iesaka Y, Kalman J, Kim YH,
Klein G, Natale A, Packer D, Skanes A. Prevalence and causes of fatal
outcome in catheter ablation of atrial fibrillation.
J Am Coll Cardiol. 2009;53:1798-1803.
3. Di Biase L, Burkhardt JD, Mohanty P, Sanchez J, Horton R,
Gallinghouse GJ, Lakkireddy D, Verma A, Khaykin Y, Hongo R, Hao S,
Beheiry S, Pelargonio G, Dello Russo A, Casella M, Santarelli P,
Santangeli P, Wang P, Al-Ahmad A, Patel D, Themistoclakis S, Bonso A,
Rossillo A, Corrado A, Raviele A, Cummings JE, Schweikert RA, Lewis WR,
Natale A. Periprocedural stroke and management of major bleeding
complications in patients undergoing catheter ablation of atrial
fibrillation: the impact of periprocedural therapeutic international
normalized ratio.
Circulation. 2010;121:2550-2556.
4. Deneke T, Jais P, Scaglione M, Schmitt R, DI Biase L, Christopoulos
G, Schade A, Mügge A, Bansmann M, Nentwich K, Müller P, Krug J, Roos M,
Halbfass P, Natale A, Gaita F, Haines D. Silent cerebral events/lesions
related to atrial fibrillation ablation: a clinical review.
J Cardiovasc Electrophysiol. 2015;26:455-463.
5. Romero J, Cerrud-Rodriguez RC, Alviz I, Diaz JC, Rodriguez D, Arshad
S, Cerna L, Taveras J, Grupposo V, Natale A, Garcia M, Di Biase L.
Significant Benefit of Uninterrupted DOACs Versus VKA During Catheter
Ablation of Atrial Fibrillation. JACC Clin Electrophysiol.
2019;5:1396-1405.
6. Steinberg BA, Shrader P, Thomas L, Ansell J, Fonarow GC, Gersh BJ,
Kowey PR, Mahaffey KW, Naccarelli G, Reiffel J, Singer DE, Peterson ED,
Piccini JP. Off-label dosing of non-vitamin K antagonist oral
anticoagulants and adverse outcomes: The ORBIT-AF II Registry.
J Am Coll Cardiol. 2016;68:2597-2604.
7. Lixana (edoxaban) [package insert]. Tokyo, Japan. Daichi Sankyo
Inc, 2015.
8. Yamaguchi T. Optimal intensity of warfarin therapy for secondary
prevention of stroke in patients with nonvalvular atrial fibrillation: a
multicenter, prospective, randomized trial. Japanese Nonvalvular Atrial
Fibrillation-Embolism Secondary Prevention Cooperative Study Group.
Stroke. 2000;31:817-821
9. Rosendaal FR, Cannegieter SC, van der Meer FJ, Brie¨t E. A method to
determine the optimal intensity of oral anticoagulant therapy. Thromb
Haemost. 1993;69:236-239.
10. Briceno DF, Villablanca PA, Lupercio F, Kargoli F, Jagannath A,
Londono A, Patel J, Otusanya O, Brevik J, Maraboto C, Berardi C,
Krumerman A, Palma E, Kim SG, Natale A, DI Biase L. Clinical Impact of
Heparin Kinetics During Catheter Ablation of Atrial Fibrillation:
Meta-Analysis and Meta-Regression. J Cardiovasc Electrophysiol.
2016;27:683-693.
11. Wardlaw JM, Smith EE, Biessels GJ, Cordonnier C, Fazekas F, Frayne
R, Lindley RI, O’Brien JT, Barkhof F, Benavente OR, Black SE, Brayne C,
Breteler M, Chabriat H, Decarli C, de Leeuw FE, Doubal F, Duering M, Fox
NC, Greenberg S, Hachinski V, Kilimann I, Mok V, Oostenbrugge Rv,
Pantoni L, Speck O, Stephan BC, Teipel S, Viswanathan A, Werring D, Chen
C, Smith C, van Buchem M, Norrving B, Gorelick PB, Dichgans M; STandards
for ReportIng Vascular changes on nEuroimaging (STRIVE v1). Neuroimaging
standards for research into small vessel disease and its contribution to
ageing and neurodegeneration. Lancet Neurol. 2013;12:822-838.
12. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on
catheter and surgical ablation of atrial fibrillation. Heart Rhythm.
2017;14:e275-e444.
13. Kirchhof P, Haeusler KG, Blank B, De Bono J, Callans D, Elvan A,
Fetsch T, Van Gelder IC, Gentlesk P, Grimaldi M, Hansen J, Hindricks G,
Al-Khalidi HR, Massaro T, Mont L, Nielsen JC, Nölker G, Piccini JP, De
Potter T, Scherr D, Schotten U, Themistoclakis S, Todd D, Vijgen J, Di
Biase L. Apixaban in patients at risk of stroke undergoing atrial
fibrillation ablation.
Eur Heart J. 2018;39:2942-2955.
14. Hohnloser SH, Camm J, Cappato R, Diener HC, Heidbüchel H, Mont L,
Morillo CA, Abozguia K, Grimaldi M, Rauer H, Reimitz PE, Smolnik R,
Mönninghoff C, Kautzner J. Uninterrupted edoxaban vs. vitamin K
antagonists for ablation of atrial fibrillation: the ELIMINATE-AF trial.
Eur Heart J. 2019;40:3013-3021.
15. Di Biase L, Briceno DF, Trivedi C, Mohanty S, Gianni C, Burkhardt
JD, Mohanty P, Bai R, Gunda S, Horton R, Bailey S, Sanchez JE, Al-Ahmad
A, Hranitzky P, Gallinghouse GJ, Reddy YM, Zagrodzky J, Hongo R, Beheiry
S, Lakkireddy D, Natale A. Is transesophageal echocardiogram mandatory
in patients undergoing ablation of atrial fibrillation with
uninterrupted novel oral anticoagulants? Results from a prospective
multicenter registry.
Heart Rhythm. 2016 Jun;13(6):1197-202.
16. Di Biase L, Gaita F, Toso E, Santangeli P, Mohanty P, Rutledge N,
Yan X, Mohanty S, Trivedi C, Bai R, Price J, Horton R, Gallinghouse GJ,
Beheiry S, Zagrodzky J, Canby R, Leclercq JF, Halimi F, Scaglione M,
Cesarani F, Faletti R, Sanchez J, Burkhardt JD, Natale A.
Does periprocedural anticoagulation management of atrial fibrillation
affect the prevalence of silent thromboembolic lesion detected by
diffusion cerebral magnetic resonance imaging in patients undergoing
radiofrequency atrial fibrillation ablation with open irrigated
catheters? Results from a prospective multicenter study. Heart Rhythm.
2014;11(5):791-798.
17. Kimura T, Kashimura S, Nishiyama T, Katsumata Y, Inagawa K, Ikegami
Y, Nishiyama N, Fukumoto K, Tanimoto Y, Aizawa Y, Tanimoto K, Fukuda K,
Takatsuki S. Asymptomatic Cerebral Infarction During Catheter Ablation
for Atrial Fibrillation: Comparing Uninterrupted Rivaroxaban and
Warfarin (ASCERTAIN). JACC Clin Electrophysiol. 2018;4:1598-1609.
18. Guijian L, Wenqing Z, Xinggang W, Ying Y, Minghui L, Yeqing X,
Ruizhen C, Junbo G.
Association between ablation technology and asymptomatic cerebral injury
following atrial fibrillation ablation. Pacing Clin Electrophysiol.
2014;37(10):1378-91.
19. Martinek M, Sigmund E, Lemes C, Derndorfer M, Aichinger J, Winter S,
Jauker W, Gschwendtner M, Nesser HJ, Pürerfellner H. Asymptomatic
cerebral lesions during pulmonary vein isolation under uninterrupted
oral anticoagulation. Europace. 2013;15:325-331.
20. Ichiki H, Oketani N, Ishida S, Iriki Y, Okui H, Maenosono R,
Ninomiya Y, Matsushita T, Miyata M, Hamasaki S, Tei C. Incidence of
asymptomatic cerebral microthromboembolism after atrial fibrillation
ablation guided by complex fractionated atrial electrogram.
J Cardiovasc Electrophysiol. 2012;23:567-573.
21. Gaita F, Caponi D, Pianelli M, Scaglione M, Toso E, Cesarani F,
Boffano C, Gandini G, Valentini MC, De Ponti R, Halimi F, Leclercq JF.
Radiofrequency catheter ablation of atrial fibrillation: a cause of
silent thromboembolism? Magnetic resonance imaging assessment of
cerebral thromboembolism in patients undergoing ablation of atrial
fibrillation. Circulation. 2010;122:1667-1673.
22. Schmidt B, Gunawardene M, Krieg D, Bordignon S, Fürnkranz A,
Kulikoglu M, Herrmann W, Chun KR. A prospective randomized single-center
study on the risk of asymptomatic cerebral lesions comparing irrigated
radiofrequency current ablation with the cryoballoon and the laser
balloon.
J Cardiovasc Electrophysiol. 2013;24:869-74.
23. Neumann T1, Kuniss M, Conradi G, Janin S, Berkowitsch A, Wojcik M,
Rixe J, Erkapic D, Zaltsberg S, Rolf A, Bachmann G, Dill T, Hamm CW,
Pitschner HF. MEDAFI-Trial (Micro-embolization during ablation of atrial
fibrillation): comparison of pulmonary vein isolation using cryoballoon
technique vs. radiofrequency energy. Europace. 2011;13:37-44.
24. Sakamoto T, Kumagai K, Nishiuchi S, Fuke E, Miki Y, Nakamura K,
Kaseno K, Koyama K, Naito S, Inoue H, Oshima S. Predictors of
asymptomatic cerebral infarction associated with radiofrequency catheter
ablation for atrial fibrillation using an irrigated-tip catheter.
Europace. 2013;15:332-338.
25. Martin AC, Kyheng M, Foissaud V, Duhamel A, Marijon E, Susen S,
Godier A. Activated Clotting Time Monitoring during Atrial Fibrillation
Catheter Ablation: Does the Anticoagulant Matter? J Clin Med. 2020;9.
pii: E350.
26. Calkins H, Willems S, Gerstenfeld EP, Verma A, Schilling R,
Hohnloser SH, Okumura K, Serota H, Nordaby M, Guiver K, Biss B, Brouwer
MA, Grimaldi M; RE-CIRCUIT Investigators. Uninterrupted Dabigatran
versus Warfarin for Ablation in Atrial Fibrillation.
N Engl J Med. 2017;376:1627-1636.
27. Hori M, Matsumoto M, Tanahashi N, Momomura S, Uchiyama S, Goto S,
Izumi T, Koretsune Y, Kajikawa M, Kato M, Ueda H, Iwamoto K, Tajiri M.
Rivaroxaban vs. warfarin in Japanese patients with atrial fibrillation
-the J-ROCKET study-. Circ J. 2012;76:2104-2111.